Evidence map›Paper›PMID 23714324›Full record

Trial reportAddiction (Abingdon, England)2013

Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.

Andrea King, Dingcai Cao, Lingjiao Zhang, Sandra Yu Rueger

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Addiction (Abingdon, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Andrea KingDepartment of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Dingcai Cao
Lingjiao Zhang
Sandra Yu Rueger
University of Chicago · USUniversity of Illinois Chicago · US

Funding

Efficacy of Naltrexone in Women's Smoking CessationR01DA016834 · NIDA · UNIVERSITY OF CHICAGO · PI KING, ANDREA C · 2005 to 2009
$3.0M
NIDA NIH HHS R01 DA016834NIDA NIH HHS R01-DA016834
6 · The paper itself

Abstract

aimsTo determine if naltrexone affects smoking behaviors in smokers preparing to quit, and whether or not such pre-quit responses predict post-quit date outcomes.

designDouble-blind, placebo-controlled, randomized study. The current study focused on smoking-related outcomes in the pre-quit phase, which was 1 week prior to the quit date, and these findings were linked with reductions in the same outcomes demonstrated in the post-quit phase published previously for this randomized controlled trial (RCT) in mediation analyses.

settingCommunity sample of adult smokers desiring to quit in Chicago, Illinois, USA.

participantsParticipants were 315 smokers randomized to naltrexone (n = 161; mean age = 42.58 years; 60% Caucasian) or placebo (n = 154; mean age = 41.32 years; 55% Caucasian). MEASUREMENTS: The difference from baseline in the number of cigarettes smoked during the pre-quit phase interval was the primary outcome. Secondary pre-quit outcomes were assessed using Likert scales of subjective responses and consumption of cigarettes, alcohol and food. Number of cigarettes smoked, alcoholic drinks consumed and the Brief Questionnaire of Smoking Urges were assessed in the post-quit phase.

findingsRelative to placebo, naltrexone decreased the number of cigarettes smoked (-4.21 versus -2.93, P < 0.05), smoking urge (P = 0.02) and number of alcoholic drinks consumed (P = 0.04). Exploratory mediation analyses linking outcomes of the pre-quit and post-quit phases found that naltrexone's effects on reducing smoking urge, cigarettes smoked and alcoholic drinks consumed in the pre-quit phase demonstrated full mediation of their respective effects during the post-quit phase.

conclusionsNaltrexone taken in the week before a quit attempt reduces cigarette consumption, urges to smoke and alcohol consumption relative to placebo. The size of the effect mediates statistically the size of similar effects after the quit date.

Indexed as

AdultAlcohol DrinkingBehavior, AddictiveChicagoDouble-Blind MethodFemaleHumansMaleMiddle AgedNaltrexoneNarcotic AntagonistsSmokingSmoking CessationTreatment OutcomeNaltrexoneNarcotic AntagonistsAlcoholcigarette smokingcotininenaltrexoneopioid antagonistsmoking urge

Identifiers

PMID23714324
PMCPMC3775903
OpenAlexW2157663379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.